Phacilitate Leaders World


Reni Benjamin

Reni Benjamin

Senior Biotechnology Analyst, Raymond James & Associates, Inc
United States

Dr. Reni Benjamin is a Senior Vice-President and Senior Biotechnology Analyst at Raymond James.  His expertise and coverage consists of companies in the oncology and stem cell sectors.  Dr. Benjamin has previously been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, been cited in a variety of sources including the Wall Street Journal, Business Week, Financial Times, and Smart Money, and has made appearances on Bloomberg television/radio and CNBC.  He has also authored a chapter in a book entitled “The Delivery of Regenerative Medicine and Their Impact on Healthcare”, and is a past member of the UAB School of Health Professions Deans Advisory Board.

Prior to joining Raymond James, Dr. Benjamin was a Managing Director and Senior Biotechnology Analyst at H.C. Wainwright, Burrill Securities and Rodman & Renshaw.    He earned his doctorate in Biochemistry and Molecular Genetics and his expertise includes biochemistry, functional genomics, gene therapy and molecular biology.  Dr. Benjamin has presented at various regional and international conferences and published in peer-reviewed journals.  Dr. Benjamin received his Ph.D. from the University of Alabama at Birmingham and his Bachelors of Science degree in Biology from Allegheny College.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman